Diaverum is announcing today that M42 has entered into a definitive agreement to acquire 100% of the company from Bridgepoint.
Diaverum, acquired by Bridgepoint in 2007, is a leading global renal care company that provides essential, life-sustaining dialysis treatments to patients in around 440 clinics across 23 countries worldwide. The company’s main focus is haemodialysis, in conjunction with a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to the coordination of patients’ comorbidities and their preparation for kidney transplantation.
Diaverum has an extensive in-house proficiency in digital transformation and Artificial Intelligence applications. Its proprietary digital care delivery model drives increased patient longevity and reduces hospitalisation, while also contributing to operational efficiency and growth. Diaverum is supported by a dedicated Management team with broad international healthcare experience, who are committed to improving medical outcomes for patients and continuing to drive innovation in digital care delivery.
M42 is a global tech-enabled healthcare holding company operating at the forefront of medical development. Established after the coming together of G42 Healthcare and Mubadala Health, M42 combines unique medical and data-centric technologies with state-of-the-art facilities to deliver the highest level of precise, patient-centric, and preventive care.
Diaverum represents a landmark strategic investment for M42 as both companies share a focus on specialty healthcare, with an aim to be at the forefront of integrating AI and technology into patient care. The combination of M42 and Diaverum represents an opportunity to leverage both companies’ clinical excellence and cutting-edge technological expertise to expand healthcare services and healthtech solutions across both existing and new markets.
Dimitris Moulavasilis, CEO of Diaverum, said: “We are pleased to join M42’s integrated global network. M42 is a perfect fit for Diaverum’s future, and the combination of the two organisations will further strengthen our position as a global leader in renal care. Together, we’ll be in an even greater position to drive international growth and continue transforming the industry through patient-centric digital innovations while delivering and broadening access to the highest quality renal care. I would also like to express my gratitude to Diaverum’s employees across the world, who make a difference in our patients’ lives every single day. They have been integral in developing Diaverum and successfully supporting this transaction.”
Hasan Jasem Al Nowais, CEO of M42, said: “M42’s acquisition of Diaverum represents a major milestone in our global expansion strategy. Diaverum is an exceptional company, providing vital treatments that enable patients suffering from chronic kidney disease to live fulfilling lives. Its pioneering digital care offering fully aligns with M42’s focus on leveraging advanced technological solutions to deliver precise, personalised patient care. I look forward to working with Diaverum’s management team to address the critical challenge that chronic kidney disease represents to countries’ healthcare services around the world.”
The deal, which is subject to customary regulatory approvals, is expected to close in the second half of 2023.
Citigroup acted as exclusive financial advisor, White & Case as legal advisor, KPMG as financial and tax advisor and LEK as commercial advisor in the transaction.